Therapeutic strategies to reduce TNF-α mediated cardiac contractile depression following ischemia and reperfusion

Journal of Molecular and Cellular Cardiology

Volumn 31, Issue 5, 1999, Pages 931-947

  Cain, Brian S ^a   Harken, Alden H ^a   Meldrum, Daniel R ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adenosine; Allopurinol; Anti oxidant; Aprotinin; Desferroxamine; Endotoxin; Estrogen; Gpl30 receptor; Heat shock; KL 10; Lisofylline; Morphine; N acetyl L cysteine; NF ; Nitric oxide; P38 MAP kinase; Phosphatidic acid; Phosphodiesterase; Phospholipase A2; Preconditioning; SAPK; Sphingosine; TNF binding protein

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; ADENOSINE; ALLOPURINOL; AMRINONE; ANTIOXIDANT; APROTININ; CYTOKINE; DEFEROXAMINE; DEXAMETHASONE; ETHANOLAMINE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; LISOFYLLINE; MEPACRINE; MILRINONE; MITOGEN ACTIVATED PROTEIN KINASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHOLIPASE A2; PIPERANOMETOZINE; SPHINGOSINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNINDEXED DRUG;

HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

EID: 0033136881     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1999.0924     Document Type: Review

References (144)

1. Abraham E, Bursten S, Shenkar R, Allbee J, Tuder R, Woodson, P, Guidot DM, Rice G, Singer JW, Repine JE. 1995. Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice. J Exp Med 181: 569-575.
2. Abraham E, Raffin TA. 1994. Sepsis therapy trials: Continued disappointment or reason for hope? JAMA 271: 1876-1878.
3. Arstall MA, Yang J, Stafford I, Betts WH, Horowitz JD. 1995. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Circulation 92: 2855-2862.
4. Barnes CR, Mandell GL, Carper HT, Luong S, Sullivan GW. 1995. Adenosine modulation of tumor necrosis factor-alpha-induced neutrophil activation. Biochem Pharmacol 50: 1851-1857.
5. Benigni F, Saco S, Pennica D, Ghezzi P. 1996. Cardiotrophin-1 inhibits tumor necrosis factor production in the heart and serum of lipopolysaccharide-treated mice and in vitro in mouse blood cells. Am J Pathol 149: 1847-1850.
6. Bergman MR, Holycross BJ. 1996. Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors. J Pharmacol Exp Ther 279: 247-254.
7. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller SJ, Ben-Levy R, Asworth A, Marshall CJ, Sugden PH. 1996. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. P38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 79: 162-173.
8. Bowlin TL, Borcherding DR, Edwards CK, Mcwinney CD. 1997. Adenosine A3 receptor agonists inhibit murine macrophage tumor necrosis factor-alpha production in vitro and in vivo. Cell Mol Biol 43: 345-349.
9. Brown JM, Terada LS, Grosso MA, Whitman GJ, Velasco SE, Patt A, Harken AH, Repine JE. 1988. Xanthine oxidase produces hydrogen peroxide which contributes to reperfusion injury of ischemic isolated rat hearts. J Clin Invest 81: 1287-1301.
10. Bulger EM, Helton WS, Clinton CM, Roque RP, Garcia I, Maier RV. 1997. Enteral vitamin E supplementation inhibits the cytokine response to endotoxin. Arch Surg 132: 1337-1341.
11. Bullough DA, Magill MJ, Firestein GS, Mullane KM. 1995. Adenosine activates A2 receptors to inhibit neutrophil adhesion and injury to isolated cardiac myocytes. J Immunol 155: 2579-2586.
12. Cain BS, Meldrum DR, Dinarello CA, Meng X, Banerjee A, Harken AH. 1998a. Adenosine reduces cardiac TNF-α production and human myocardial injury following ischemia-reperfusion. J Surg Res 76: 117-123.
13. Cain BS, Meldrum DR, Dinarello CA, Meng X, Banerjee A, Harken AH. 1998b. Tnf-α and IL-1β synergistically depress human myocardial function. Crit Care Med In Press.
14. Cain BS, Meldrum DR, Harken AH, Mcintyre RC. 1998c. Physiologic basis for anti-cytokine clinical trials in the treatment of sepsis. J Am Coll Surg 186: 337-350.
15. Cain BS, Meldrum DR, Selzman C, Sheridan BC, Meng X, Banerjee A, Harken AH. 1997. Surgical implications of vascular endothelial physiology. Surgery 122: 516-526.
16. Chandrasekar B, Colston JT, Freeman GL. 1997a. Induction of proinflammatory cytokine and antioxidant enzyme gene expression following brief myocardial ischemia. Clin Exp Immunol 108: 346-351.
17. Chandrasekar B, Freeman GL. 1997b. Induction of nuclear factor kappaB and activation protein 1 in postischemic myocardium. FEBS Lett 401: 30-34.
18. Chandrasekar B, Streitman JE, Colston JT, Freeman GL. 1998. Inhibition of nuclear factor kappaB attenuates proinflammatory cytokine and inducible nitric-oxide synthase expression in postischemic myocardium. BiOchim Biophys Acta 1406: 91-106.
19. Chen GJ, Watson RR. 1991. Modulation of tumor-necrosis factor and gamma production by cocaine and morphine in aging mice infected with LP-BM5, a murine retrovirus. J Leukoc Biol 50: 349-355.
20. Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolfe SM, Dinarello CA. 1995. A randomized, controlled trial of IL-10 in humans. J Immunol 154: 5492-5499.
21. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL. 1986. Biologic effects of transdermal estradiol. N Engl J Med 314: 1615-20.
22. Cleveland JC, Meldrum DR, Cain BS, Banerjee A, Harken AH. 1997a. Oral sulfonylurea agents prevent ischemic preconditioning in human myocardium. Circulation 96: 29-32.
23. 1-adrenoceptors. Am J Physiol 273: H902-H908.
24. Coghlan JG, Flitter WD, Clutton SM, Panda R, Daly R, Wright G, Ilsley CD, Slater TF. 1994. Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 107: 248-256.
25. Collis CS, Davies MJ, Rice-Evans C. 1993. Comparison of N-methyl hexanoylhydroxamic acid, a novel anti-oxidant, with desferrioxamine and N-acetyl cysteine against reperfusion-induced dysfunctions in isolated rat heart. J Cardiovasc Pharmacol 22: 336-342.
26. Coroneos E, Matinez M, McKenna S, Kester M. 1995. Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines. Implications for cellular proliferation and differentiation. J Biol Chem 270: 23305-23309.
27. Das DK, Engelman RM, Rousou JA, Breyer RH, Otani H, Lemeshow S. 1986. Role of membrane phospholipids in myocardial injury induced by ischemia and reperfusion. Am J Physiol 251: H71-H79.
28. Dinarello CA. 1996. Biologic basis for Interleukin-1 in disease. Blood 87: 2095-2147.
29. Engles RE, Huber TS, Zander DS, Hess PJ, Welborn MB, Moldawer LL, Seeger JM. 1997. Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia-reperfusion injury. J Surg Res 69: 425-428.
30. Farivar RS, Brecher P. 1996. Salicylate is a transcriptional inhibitor of the inducible nitric oxide synthase in cultured cardiac fibroblasts. J Biol Chem 1: 31585-31592.
31. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Summons RL. 1992. Negative notropic effects of cytokines on the heart mediated by nitric oxide. Science 257: 387-389.
32. Forman MB, Puett DW, Cates CU, Mccroskey DE, Beckman JK, Greene HL, Virmani R. 1988. Glutathione redox pathway and reperfusion injury. Effect of N-acetylcysteine on infarct size and ventricular function. Circulation 78: 202-213.
33. Fukuzawa M, Satoh J, Muto G, Muto Y, Nishimura S, Miyaguchi S, Qiang XL, Toyota T. 1997. Inhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor-alpha. Immunol Lett 59: 7-11.
34. Fyfe A, Daly P, Gallican L, Pirc L, Feindel C, Cardella C. 1993. Coronary sinus sampling of cytokines after heart transplantation: Evidence for macrophage activation and interleukin-4 production within the graft. J Am Coll Cardiol 21: 171-176.
35. i and contractility in isolated adult rabbit ventricular myocytes. Am J Physiol 271: H1449-H1455.
36. Gurevitch J, Frolkis I, Yuhas Y, Lifschitz-Mercer B, Berger E, Paz Y, Matsa M, Kramer A, Mohr R. 1997. Anti-tumor necrosis factor-alpha improves myocardial recovery after ischemia and reperfusion. J Am Coll Cardiol 30: 1554-1561.
37. Gurevitch J, Frolkis I, Yuhas Y, Paz Y, Matsa M, Mohr R, Yakirevich V. 1996. Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion. J Am Coll Cardiol 28: 247-252.
38. Hannun YA. 1996. Functions of ceramide in coordinating the metabolic response to stress. Science 274: 1855-1859.
39. Harken AH. Cardiac Dysrhythmias. In: Scientific American Surgery, edited by Wilmore DA, Cheung LY, Harken AH, Holcroft JW and Meakins JL. New York: Scientific American, Inc., 1997, 13.
40. Hasko G, Sczabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES. 1996. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 157: 4634-4640.
41. Herskowitz AS, Choi S, Ansari AA, Wesselingh S. 1995. Cytokine mRNA expression in the postischemic/ reperfused myocardium. Am J Pathol 146: 419-428.
42. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. 1995. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 110: 1658-1662.
43. Hill GE, Springall DR, Robbins RA. 1997. Aprotinin is associated with a decrease in nitric oxide production during cardiopulmonary bypass. Surgery 121: 449-455.
44. Hoffen EV, Wichen DV, Stuij I, Jonge ND, Klopping C, Lahpor J, Den JV, Tweel J, Gmelig-Meyling F, Weger RD. 1996. In situ expression of cytokines in human heart allografts. Am J Pathol 149: 1991-2003.
45. Howard M, Muchamel T, Andrade S, Menon S. 1993. Interleukin 10 protects mice from lethal endotoxinemia. J Exp Med 177: 1205-1208.
46. Jansen NJ,Vanoeveren W, Vandenbroek HM HMO-vS. HM, Stoutenbeek CP, Joen MC, Roozendaal KJ, Eysman L, Wildevuur CR. 1991. Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. J Thorac Cardiovasc Surg 102: 515-525.
47. Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, Reed JC, Olivetti G, Anversa P. 1996. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 74: 86-107.
48. Kanda T, Mcmanus JE, Nagai R, Imai S, Suzuki T, Yang D, Mcmanus BM, Kobayashi I. 1996. Modification of viral myocarditis in mice by interleukin-6. Circ Res 78: 848-856.
49. Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL. 1995. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 96: 1042-1052.
50. Kawano K, Kim YI, Kai T, Ishii T, Tatsuma T, Morimoto A, Tamura Y, Kobayashi M. 1994. Evidence that FK506 alleviates ischemia/reperfusion injury to the rat liver: In vivo demonstration for suppression of TNF-α production in response to endotoxemia. Eur Surg Res 26: 108-115.
51. Kilbourn RG, Szabo C, Traber DL. 1997. Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: Lessons learned from experimental and clinical studies. Shock 7: 235-246.
52. 2+ transients. FEBS Lett 376: 24-30.
53. Kubota T, Mcnamara DM, Wang JJ, Trost M, Mctiernan CF, Mann DL, Feldman AM. 1998. Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST investigators of TNF genotype analysis. Vesnarinone survival trial. Circulation 97: 2499-2501.
54. Kubota T, Mctiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetrius AJ, Feldman AM. 1997. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81: 627-635.
55. Kukielka GL, Smith CW, Manning AM, Youker KA, Michael LH, Entman ML. 1995. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation 92: 1866-1875.
56. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. 1996. Tumor necrosis factor-alpha and interleukin 1-beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 3: 949-958.
57. Latini R, Bianchi M, Correale E, Dinarello CA, Fantuzzi G, Fresco C, Maggoini AP, Mengozzi M, Romano S, Shapiro L. 1994. Cytokines in acute myocardial infarction: Selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin 1 receptor antagonist. J Cardiovasc Pharmacol 23: 1-6.
58. Lee HT, Lafaro RJ, Reed GE. 1995. Pretreatment of human myocardium with adenosine during open heart surgery. J Card Surg 10: 665-676.
59. Lee JC, Young PR. 1996. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J Leukoc Biol 59: 152-157.
60. Lemoine O, Louis H, Stordeur P, Collet JM, Goldman M, Deviere J. 1997. Role of reactive oxygen intermediates in interleukin 10 release after cold liver ischemia and reperfusion in mice. Gastroenterology 113: 1701-1706.
61. Levine B, Kalman J, Mayer L, Fillit H, Packer M. 1990. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Eng J Med 323: 236-241.
62. Mann DL. 1996. Stress activated cytokines and the heart. Cytokine Growth Factor Rev 7: 341-354.
63. Mathias S, Dressler KA, Kolesnik RN. 1991. Characterization of a ceramide-activated protein kinase: Stimulation by tumor necrosis factor alpha. Proc Natl Acad Sci (USA) 88: 10009-10013.
64. Matsui S, Matsumori A, Matoba Y, Uchida A, Sasayama S. 1994. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production. J Clin Invest 94: 1212-1217.
65. Matsumori A, Ono K, Nishio R, Igata H, Shioi T, Matsui S, Furukawa Y, Iwasaki A, Nose Y, Sasayama S. 1997. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation 96: 1501-1506.
66. Matsumori A, Ono K, Sato Y, Shioi T, Nose Y, Sasayama S. 1996. Differential modulation of cytokine production by drugs: Implications for therapy in heart failure. J Mol Cell Cardiol 28: 2491-2499.
67. Meldrum DR. 1997. Mechanisms of cardiac preconditioning: Ten years after the discovery of ischemia preconditioning. J Surg Res 73: 1-13.
68. Meldrum DR. 1998. Tumor necrosis factor in the heart. Am J Physiol 274: R577-R595.
69. 31P-NMR Surgery 112: 150-158.
70. Meldrum DR, Ayala A, Chaudry IH. 1993. Mechanism of diltiazem's immunoprotective effects following hemorrhage and resuscitation. Am J Physiol 265: C412-C421.
71. 2 restores energetics and decreases lethality. J Surg Res 57: 55-61.
72. Meldrum DR, Ayala A, Perrin M, Ertel W, Chaudry IH. 1991a. Diltiazem restores IL-2, IL-3, IL-6, and IFN-γ synthesis and decreases host susceptibility to sepsis following hemorrhage. J Surg Res 51: 158-164.
73. 2. Am J Physiol 261: R351-357.
74. Meldrum DR, Cain BS, Cleveland JC, Meng X, Ayala A, Harken AH. 1997a. Adenosine decreases post-ischemic myocardial TNFα: Anti-inflammatory implications for preconditioning and transplantation. ImMunology 92: 472-477.
75. Meldrum DR, Cleveland JC, Cain BS, Meng X, Harken AH. 1998a. Increased myocardial TNFα in a crystalloid perfused model of cardiac ischemia-reperfusion injury. Ann Thorac Surg 65: 439-443.
76. Meldrum DR, Cleveland JC, Cain BS, Shames BD, Meng X, Banerjee A, Harken AH. 1998b. Ischemic preconditioning downregulates post-ischemic myocardial tumor necrosis factor-α production: Potential ultimate effector mechanism of preconditioning. Circulation 98: II-214-219.
77. Meldrum DR, Cleveland JC, Meng X, Sheridan BC, Gamboni F, Cain BS, Harken AH, Banerjee A. 1997b. Protein kinase C isoform diversity in preconditioning. J Surg Res 69: 183-187.
78. Meldrum DR, Cleveland JC, Moore EE, Partrick DA, Banerjee A, Harken AH. 1997c. Adaptive and maladaptive mechanisms of cellular priming. Ann Surg 226: 587-598.
79. Meldrum DR, Cleveland JC and Rowland RT, Banerjee A, Harken AH, Meng X. 1997d. Early and delayed preconditioning: Differential mechanisms and additive protection. Am J Physiol 273: H725-H733.
80. Meldrum DR, Cleveland JC, Sheridan BC, Rowland RT, Banerjee A, Harken AH. 1996a. Cardiac surgical implications of calcium dyshomeostasis in the heart. Ann Thorac Surg 61: 1273-1280.
81. Meldrum DR, Cleveland JC, Sheridan BC, Rowland RT, Banerjee A, Harken AH. 1996b. Differential effects of adenosine preconditioning on the postischemic rat myocardium. J Surg Res 65: 159-164.
82. Meldrum DR, Cleveland JC, Sheridan BC, Rowland RT, Selzman CH, Banerjee A, Harken AH. 1997e. Alpha-adrenergic activation of myocardial NFκb during hemorrhage. J Surg Res 69: 268-276.
83. Meldrum DR, Dinarello CA, Cleveland JC, Cain BS, Shames BD, Meng X, Harken AH. 1998c. Hydrogen peroxide induces tumor necrosis factor-alpha mediated cardiac injury by a p38 mitogen activated protein kinase dependent mechanism. Surgery 124: 291-297.
84. Meldrum DR, Dinarello CA, Meng X, Shapiro L, Harken AH. 1997f. P38 MAP kinase-mediated myocardial TNFα production contributes to post-ischemic cardiac dysfunction. Circulation 96 (Suppl): I-556.
85. Meldrum DR, Meng X, Dinarello CA, Ayala A, Cain BS, Shames BD, Ao L, Banerjee A, Harken AH. 1998d. Human myocardial tissue TNFα expression following acute global ischemia in vivo. J Moll Cell Cardiol 30: 1683-1689.
86. Meldrum DR, Meng X, Sheridan BC, Mcintyre RC, Harken AH, Banerjee A. 1998e. Tissue-specific protein kinase C isoforms differentially mediate macrophage TNFα and IL-1β production. Shock 9: 256-260.
87. Meldrum DR Shenkar R, Sheridan BC, Cain BS, Abraham E, Harken AH. 1997g. Hemorrhage activates myocardial NFkB and increases TNF-alpha in the heart. J Mol Cell Cardiol 29: 2849-2854.
88. Meng X, Ao L, Brown JM, Meldrum DR, Sheridan BC, Cain BS, Banerjee A, Harken AH. 1997. LPS induces late cardiac functional protection against ischemia independent of cardiac and circulating TNFα Am J Physiol 273: H1894-H1902.
89. Murray DR, Freeman GL. 1995. Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res 78: 154-160.
90. Natanson C Hoffman WD, Suffredini AF, Eichacker PQ, Dranner RL. 1994. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 120: 771-783.
91. Nathens AB Bitar R, Davreux C, Bujard M, Marshall JC, Dackiw AP, Watson RW, Rotstein OD. 1997. Pyrrolidine dithiocarbamate attenuates endotoxin-induced acute lung injury. Am J Respir Cell Mol Biol 17: 608-616.
92. Oral H Dorn GW, Mann DL. 1997. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mamalian cardiac myocyte. J Biol Chem 272: 4836-4872.
93. Oral H Kapadia S, Nakano M, Torre-Amione G, Lee J, Lee-Jackson D, Young JB, Mann DL. 1995. Tumor necrosis factor alpha and the failing human heart. Clin Cardiol 8: IV20-IV27.
94. Parmely MJ Zhou WW, Edwards CK, Borcherding DR, Silvertein R, Morrison DC. 1993. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol 151: 389-396.
95. Pellicane JV, Demaria EJ, Abd-Elfattah A, Reines HD, Vannice JL, Carson KW. 1993. Interleukin-1 receptor antagonist improves survival and preserves organ adenosine-5′-triphosphate after hemorrhagic shock. Surgery 114: 278-283.
96. Prasad MR, Popescu LM, Moraru II, Liu XK, Maity S, Engelman RM, Das DK. 1991. Role of phospholipases A2 and C in myocardial ischemic reperfusion injury. Am J Physiol 260: H877-H883.
97. Qiu Y, Bernier M, Hearse DJ. 1990. The influence of N-acetylcysteine on cardiac function and rhythm disorders during ischemia and reperfusion. Cardioscience 1: 65-74.
98. Redlich CA, Gao X, Rockwell S, Kelly M, Elias JA. 1996. IL-11 enhances survival and decreases TNF production after radiation-induced thoracic injury. J Immunol 157: 1705-1710.
99. Rice GC, Brown PA, Nelson RJ, Bianco JA, Singer JW, Bursten S. 1994a. Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc Natl Acad Sci USA 91: 3857-3861.
100. Rice GC, Rosen J, Weeks R, Michnick J, Bursten S, Bianco JA, Singer JW. 1994b. CT-1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo. Shock 1: 254-266.
101. Riche F, Panis Y, Laisne MJ, Briard C, Cholley B, Bernard-Poenaru O, Graulet AM, Gueris J, Valleur P. 1996. High tumor necrosis factor serum level is associated with increased survival in patients with abdominal septic shock: A prospective study in 59 patients. Surgery 120: 801-807.
102. Ritchie PK, Spangelo BL, Krzymowski DK, Rossiter TB, Kurth E, Judd AM. 1997. Adenosine increases interleukin 6 and deceases tumour necrosis factor release from rat adrenal zona glomerulosa cells, ovarian cells, anterior pituitary cells, and peritoneal macrophages. Cytokine 9: 187-198.
103. Sabbadini RA, Betto R, Teresi A, Fachechi-Cassano G, Salviati G. 1992. The effects of sphingosine on sarcoplasmic reticulum calcium release. J Biol Chem 267: 15475-15484.
104. Sadoff J. Soluble TNF reports. In: Third International Congress of the Immune Consequences of Trauma, Shock, and Sepsis., edited by Munich, Germany: 1994.
105. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS. 1996. Inhibition of TNF-alpha expression by adenosine: Role of A3 adenosine receptors. J Immunol 156: 3435-3442.
106. Schultz JE, Hsu AK, Gross GJ. 1996. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res 78: 1100-1104.
107. Schultz JJ, Hsu AK, Gross GJ. 1997. Ischemic preconditioning and morphine-induced cardioprotection involve the delta (delta)-opioid receptor in the intact rat heart. J Mol Cell Cardiol 29: 2187-2195.
108. Schulz R, Wambolt R. 1995. Inhibition of nitric oxide synthesis protects the isolated working rabbit heart from ischaemia-reperfusion injury. Cardiovasc Res 30: 432-439.
109. Schwartz MD, Repine JE, Abraham E. 1995. Xanthine oxidase-derived oxygen radicals increase lung cytokine expression in mice subjected to hemorrhagic shock. Am J Respir Cell Mol Biol 12: 434-440.
110. Selzman CH, Whitehill TA, Shames BD, Pulido EJ, Cain BS, Harken AH. 1998. The biology of estrogen-mediated repair of cardiovascular injury. Ann Thorac Surg 65: 868-874.
111. Semmler J, Gebert U, Eisenhut T, Moeller J, Schonharting MM, Allera A, Endres S. 1993. Xanthine derivatives: Comparison between supression of tumour necrosis factor-alpha production and inhibition of cAMP posphodiesterase activity. Immunology 78: 520-525.
112. Sexl V, Mancusi G, Holler C, Gloria-Maercker E, Schutz W, Freissmuth M. 1997. Stimulation of the mitogen-activated protein kinase via the A2A-adenosine receptor in primary human endothelial cells. J Biol Chem 272: 5792-5799.
113. Shames BD, Meldrum DR, Selzman CH, Pulido EJ, Cain BS, Banerjee A, Harken AH, Meng X. 1998. Myocardial IκB-α is induced and stabilized in endotoxin tolerant rats. Am J Physiol 275: H1084-1091.
114. Shen CY, Wang D, Chang ML, Hsu K. 1995. Protective effect of mepacrine on hypoxia-reoxygenation-induced acute lung injury in rats. J Appl Physiol 78: 225-231.
115. Sheridan BC, Dinarello CA, Meldrum DR, Selzman CH, Fullerton DA, Mcintyre RC. 1999. Interleukin 11 attenuates cGMP mediated pulmonary vasomotor dysfunction during acute lung injury. Am J Physiol (in press).
116. Shibata T, Yamamoto F, Suehiro S, Kinoshita H. 1997. Effects of protease inhibitors on postichemic recovery of the heart. Cardiovasc Drugs Ther 11: 547-556.
117. Shito M, Wakabayashi G, Ueda M, Shimazu M, Shirasugi N, Endo M, Mukai M, Kitajima M. 1997. Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemi-reperfusion in the rat. Transplantation 63: 143-148.
118. Squadrito F, Altavilla D, Squadrito G, Campo GM, Arlotta M, Arcoraci V, Minutoli L, Serrano M, Saitta A, Caputi AP. 1997. 17beta-oestradiol reduces cardiac leukocyte accumulation in myocardial ischaemia reperfusion injury in rat. Eur J Pharmacol 335: 185-192.
119. Squadrito F, Altavilla D, Zingarelli B, Ioculano M, Calapai G, Campo, GM, Miceli A, Caputi AP. 1993a. Tumor necrosis factor involvement in ischaemia-reperfusion. Eur J Pharmacol 237: 223-230.
120. Ap. 1993b. The effect of cloricromene, a coumarine derivative, on leukocyte accumulation, myocardial necrosis and TNF-alpha production in myocardial ischaemia-reperfusion injury. Life Sci 53: 341-355.
121. Stouthard JM Romijn JA, Vanderpoll T, Endert E, Klein S, Bakker PJ, Veenhof CH, Sauerwein HP. 1995. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol 268: E813-E819.
122. Taga T, Kishimoto T. 1997. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15: 797-819.
123. Tang LD, Sun JZ, Wu K, Sun CP, Tang ZM. 1991. Beneficial effects of N-acetylcysteine and cysteine in stunned myocardium in perfused rat heart. Br J Pharmacol 102: 601-606.
124. Teoh KH, Bradley CA, Gauldie J, Burrows H. 1995. Steroid inhibition of cytokine-mediated vasodilation after warm heart surgery. Circulation 92: II347-II353.
125. Tracey KJ, BEutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW et al 1986. Shock and tissue injury induced by recombinant human cachectin. Science 234: 470-474.
126. Trepicchio WL, Bozza M, Pedneault G, Dorner AJ. 1996. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of pro-inflammatory cytokine release and nitric oxide production. J Immunol 157: 3627-3634.
127. Tuomainen TP, Punnonen K, Nyyssonen K, Salonen JT. 1998. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 97: 1461-1466.
128. Vanjaarsveld H, Kuyl JM, Wiid NM. 1994. Ischemia/reperfusion injury is aggravated by an iron supplemented diet and is partly prevented by simultaneous antioxidant supplementation. Res Commun Mol Pathol Pharmacol 86: 273-285.
129. Wagner DR, Combes A, Mctiernan C, Sanders VJ, Lemster B, Feldman AM. 1998a. Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor. Circ Res 82: 47-56.
130. Wagner DR, Mctiernan C, Sanders VJ, Feldman AM. 1998b. Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-alpha in the failing human heart. Circulation 97: 521-524.
131. Wan S, Desmet JM, Barvais L, Goldstein M, Vincent JL, Leclerc JL. 1996a. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 112: 806-811.
132. Wan S, Marchant A, Desmet JM, Antoine M, Zhang H, Vachiery JL, Goldman M, Vincent JL, Leclerc JL. 1996b. Human cytokine responses to cardiac transplantation and coronary bypass grafting. J Thorac Cardiovasc Surg 111: 469-477.
133. Wang P, Zweier JL. 1996. Measurement of nitric oxide and peroxynitrite generation in the postischemic heart: Evidence for peroxynitrite-mediated reperfusion injury. J Biol Chem 271: 29223-29230.
134. Waxman K, Daughters K, Aswani S, Rice G. 1996. Lisophyilline decreases white cell adhesiveness and improves survival after experimental hemorrhagic shock. Crit Care Med 24: 1724-1728.
135. Whitley WD Hancock WW, Kupiec-Weglinski Jw, Desousa M, Tilney NL. 1993. Iron chelation suppresses mononuclear cell activation, modifies lymphocyte migration patterns, and prolongs rat cardiac allograft survival in rats. Transplantation 56: 1182-1188.
136. Whitmarsh AJ, Yang SH, Su MS, Sharrocks AD, Davis RJ. 1997. Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors. Mol Cell Biol 17: 2360-2371.
137. Woolfson RG, Patel VC, Neild GH, Yellon DM. 1995. Inhibition of nitric oxide synthesis reduces infarct size by an adenosine-dependent mechanism. Circulation 91: 1545-1551.
138. Yang YC, Yin T. 1995. Interleukin (IL)-11-mediated signal transduction. Ann NY Acad Sci 762: 31-40.
139. Yokoyama T, Nakano M, Bednarczyk JL, Mcintyre BW, Entman M, Mann DL. 1997. Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 95: 1247-1252.
140. Young PR, Mclaughlin MM, Kumar S, Kassis S, Doyle ML, Mcnulty D et al. 1997. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 272: 12116-12121.
141. Yue TL, Ma XL, Wang X, Romanic AM, Liu GL, Louden C, Gu JL, Kumar S, Poste G, Ruffolo RR Jr, Feuerstein GZ. 1998. Possible involvement of stress-activated protein kinase signaling pathway and fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res 82: 166-174.
142. Zhang H, Spapen H, Nguyen DN, Benlabed M, Buurman Wa, Vincent JL. 1994. Protective effects of N-acetyl-L-cysteine in endotoxemia. Am J Physiol 266: H1764-H1754.
143. Ziegler-Heitbrock HW, Sternsdorf T, Liese J, BElohradsky B, Weber C, Wedel A, Schreck R, Bauerle P, Strobel, M. 1993. Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes. J Immunol 151: 6986-6993.
144. Zingarelli B, Carnuccio R, Dirosa M. 1993. Cloricromene inhibits the induction of nitric oxide synthase. Eur J Pharmacol 243: 107-111.